Portada›Lunes 5 de enero de 2026

Biomédicas del NASDAQ ante la SEC, lunes 5 de enero de 2026

Los 25 documentos que 22 empresas del sector presentaron ante la SEC ese día, agrupados por tipo y con el enlace al original en EDGAR.

← viernes 2 de enero de 2026 · martes 6 de enero de 2026 →

Va en color lo que cambia el capital o avisa de un riesgo: las emisiones con precio (424B1, 424B2, 424B4 y 424B5), los 8-K con item 1.02, 1.03, 2.04, 3.01, 3.02 y 4.02, y cualquier documento en el que haya aparecido una frase vigilada, que va citada debajo. Lo demás va en tinta normal. Una cita marcada «por primera vez» es una frase que no estaba en el informe previo del mismo tipo de esa empresa. La etiqueta del formulario lleva a su explicación.

Emisiones y dilución

1. AKTSAktis Oncology, Inc.S-1/ACapacidad de emisión registrada (enmienda)EDGAR
2. CRNXCrinetics Pharmaceuticals, Inc.424B5Nueva emisión de acciones con precioEDGAR
3. CTORCITIUS ONCOLOGY, INC.S-3Capacidad de emisión registradaEDGAR
   En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸

   …results to differ materially from those expressed in such forward-looking statements: ● our independent registered public accounting firm’s report includes an explanatory paragraph stating that there is substantial doubt about our ability to continue as a going concern; ● our need for substantial additional funds and our ability to raise those funds; ● our ongoing evaluation of strategic alternatives; ● our ability to successfully commercialize LYMPHIR, including covering…
4. MTVAMetaVia Inc.S-1Capacidad de emisión registradaEDGAR
   En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸

   …cash flows from operating activities since our inception, and we have a net loss of $11.0 million and an accumulated deficit of $146.9 million as of September 30, 2025. We have concluded that there is substantial doubt about the Company’s ability to continue as a going concern within twelve months from the date the consolidated financial statements were issued. Our independent registered public accounting firm has issued an opinion on our consolidated financial statements included…

   En el documentoContrasplit de accionestexto original ▸

   …this offering. Each Series C Common Warrant will be exercisable immediately upon issuance, have a term of five years from the date of issuance and an exercise price equal to $ . On December 4, 2025, we effected a 1-for-11 reverse stock split of our common stock (the “Reverse Stock Split”). All information presented in this prospectus has been adjusted to account for the Reverse Stock Split, and unless otherwise indicated, all such amounts…

   En el documentoPrograma de venta continua de acciones (ATM)texto original ▸

   …condensed consolidated financial statements and related notes for the three and nine months ended September 30, 2025 included elsewhere in this prospectus. At-The-Market Offering On November 6, 2025, we entered into an At The Market Offering Agreement (the “Sales Agreement”) with Ladenburg Thalmann & Co. Inc., as sales agent and/or principal (“Ladenburg”), pursuant to which we may offer and sell, from time to time through or to Ladenburg…
5. IPSCCentury Therapeutics, Inc.S-3/ACapacidad de emisión registrada (enmienda)EDGAR

Participaciones y control

1. DBVTDBV Technologies S.A.SC 13D/ACambio en participación significativaEDGAR
2. EXELEXELIXIS, INC.SC 13D/ACambio en participación significativaEDGAR
3. FBIOFortress Biotech, Inc.SC 13D/ACambio en participación significativaEDGAR
4. PLURPluri Inc.SC 13D/ACambio en participación significativaEDGAR

Informes y hechos relevantes

1. HYPDHYPERION DEFI, INC.8-KVenta de acciones no registrada (colocación privada)EDGAR
   En el documentoCambio en la dirección de la empresatexto original ▸

   …Appoints Robert Rubenstein as General Counsel LAGUNA HILLS, Calif., January 5, 2026 — Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the “Company”) today announced that its Board of Directors has appointed Hyunsu Jung as Chief Executive Officer, effective immediately. Mr. Jung’s appointment marks an important milestone in the Company’s leadership evolution as it advances its strategic priorities for 2026. Mr. Jung joined Hyperion DeFi as Chief…
2. ZBIOZenas BioPharma, Inc.8-KResultadosEDGAR
   En el documentoEl ensayo alcanzó su objetivo principaltexto original ▸

   …tm261774d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) - Obexelimab met the primary endpoint demonstrating a clinically meaningful and highly statistically significant 56% reduction in risk of IgG4-RD flare - - Obexelimab also met and demonstrated statistically significant activity on all four…
3. CRNXCrinetics Pharmaceuticals, Inc.8-KResultadosEDGAR
4. CURXCuranex Pharmaceuticals Inc8-KCambio en el consejo o la direcciónEDGAR
   En el documentoCambio en la dirección de la empresatexto original ▸

   …Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On December 31, 2025, Haiyan Yang informed Curanex Pharmaceuticals Inc, a Nevada corporation (the “Company”) of her resignation as Chief Financial Officer and Treasurer of the Company, effective immediately. Ms. Yang’s decision to resign was not due to any disagreement relating to the Company’s operations, policies or practices. On December 31, 2025, in…
5. DMACDiaMedica Therapeutics Inc.8-KOtros hechos relevantesEDGAR
6. GNLXGENELUX Corp8-KOtros hechos relevantesEDGAR
7. GPCRStructure Therapeutics Inc.8-KNuevo acuerdo materialEDGAR
8. IMUXIMMUNIC, INC.8-KCambio en el consejo o la direcciónEDGAR
9. ISPCiSpecimen Inc.8-KNuevo acuerdo materialEDGAR
10. ISPCiSpecimen Inc.8-KOtros hechos relevantesEDGAR
11. JBIOJade Biosciences, Inc.8-KResultadosEDGAR
12. MTVAMetaVia Inc.8-KResultadosEDGAR
13. NMRANeumora Therapeutics, Inc.8-KOtros hechos relevantesEDGAR
14. RMTIROCKWELL MEDICAL, INC.8-KOtros hechos relevantesEDGAR
15. TELOTelomir Pharmaceuticals, Inc.8-KOtros hechos relevantesEDGAR
16. TNGXTango Therapeutics, Inc.8-KCambio en el consejo o la direcciónEDGAR

← viernes 2 de enero de 2026 · martes 6 de enero de 2026 →

Esto mismo, cada mañana y solo de tus empresas. Sigue a las que te interesen y recibe en tu correo lo que presenten ante la SEC, en castellano. Crear una cuenta. ¿Ya tienes cuenta? Entrar.

Esto no son recomendaciones de inversión. Son hechos públicos verificables en su fuente. Lee siempre el documento original antes de decidir nada. Aviso legal.